Rheumatoid Arthritis: Introduction, Etiology, and Pathophysiology

1. Introduction

• Anti-citrullinated protein antibodies (ACPAs) - present in ~70% of patients, and strongly predictive of erosive disease
• Rheumatoid factor (RF) - IgM antibody against the Fc fragment of IgG, present in ~70-80%

2. Etiology

2.1 Genetic Factors

• The HLA-DRB1 gene is the dominant genetic locus, accounting for approximately 60% of the genetic load.
• Stastny first identified the association of RA with HLA-DR4 (DRB10401) in the 1970s. Subsequent work defined the concept of the "shared epitope" (SE) - a conserved amino acid sequence (QKRAA or QRRAA) at positions 70-74 of the HLA-DRB1 chain, present across multiple alleles (DRB10401, *0404, *0405, *0101).
• The shared epitope specifically binds and presents citrullinated self-peptides to T cells, directly linking HLA genetics to ACPA generation and disease susceptibility.
• Heterozygosity for HLA-DRB1 alleles confers additional risk for severe, nodular disease.

• PTPN22 - encodes lymphoid tyrosine phosphatase, regulates T and B cell receptor signaling. Associated with multiple autoimmune diseases including RA, T1DM, SLE, and JIA.
• STAT4 - associated with RA, SLE, systemic sclerosis, and Sjogren's syndrome, suggesting shared inflammatory pathways
• Other loci include CTLA4, TRAF1-C5, FCGR3A, PADI4 (encoding peptidylarginine deiminase 4, directly implicated in citrullination)

2.2 Environmental Factors

• Smoking promotes peptide citrullination via PAD2 and PAD4 activation in the lungs and airways
• Induces ACPA responses in genetically predisposed individuals (particularly those with HLA shared epitope)
• Gene-environment interaction: smoking combined with HLA-SE dramatically amplifies ACPA-positive RA risk

• Strong bidirectional association between RA and periodontitis - PD is more common in RA, especially ACPA-positive patients
• Porphyromonas gingivalis expresses its own PAD enzyme (PPAD), capable of citrullinating host and bacterial proteins
• Other periodontal pathogens implicated include Tannerella forsythia, Treponema denticola, and Aggregatibacter actinomycetemcomitans
• Repeated bacteremia from oral organisms coincides with disease flares and drives innate immune activation and ACPA expansion

• Altered intestinal microbiota precede clinical RA. Changes in gut microbial composition shift immune homeostasis toward pro-inflammatory states
• Metabolomic studies show significant systemic metabolic changes - including alterations in tryptophan/kynurenine pathways, lactate, and lipid oxidation - that precede overt RA onset by years
• The hypoxic RA joint shows high intra-articular lactate, low glucose, and elevated ketone bodies reflecting altered metabolic microenvironment

• Hormonal factors: female predominance, disease flares post-partum, and improvement during pregnancy suggest a role for sex hormones
• Occupational exposures: silica dust, mineral oils
• Infections: several pathogens (EBV, Mycobacterium, Proteus mirabilis) have been proposed as triggers via molecular mimicry, though none proven causal

3. Pathophysiology

3.1 Phase 1 - Pre-clinical Phase (Systemic Autoimmunity without Joint Involvement)

• Local inflammatory stimuli (smoking, periodontal disease, microbial dysbiosis) drive increased citrullination of host proteins via peptidylarginine deiminase (PAD) enzymes released from apoptosing granulocytes and monocytes
• The HLA-DRB1 shared epitope specifically binds and presents citrullinated self-peptides (fibrinogen, vimentin, alpha-enolase, collagen type II) to autoreactive CD4+ T cells
• Isotype-switched IgA and IgG ACPAs appear - often detectable 5-10 years before symptom onset
• Higher ACPA titers and broader ACPA repertoire predict subsequent progression to clinical disease
• Neutrophil extracellular traps (NETs) - a form of neutrophil cell death - release citrullinated chromatin and active PAD isoforms into the airways and joints, further amplifying the ACPA response

3.2 Phase 2 - Early Clinically Evident Disease

• Immune complex deposition: Citrullinated antigen-ACPA immune complexes deposit in the synovium, activating complement and Fc receptor-bearing cells
• RF-containing immune complexes form and drive acute synovial inflammation
• Activation of innate immunity: macrophages, dendritic cells, and mast cells in the synovium secrete TNF-alpha, IL-1beta, IL-6, IL-17, and IL-18
• T cell activation: CD4+ Th1 and Th17 cells accumulate in the synovium, driven by IL-12 and IL-23 respectively. Th17 cells are particularly important drivers of osteoclast activation via RANKL
• B cell responses: Plasma cells in the synovium produce RF and ACPA locally; autoantibody-containing immune complexes perpetuate inflammation

3.3 Phase 3 - Established Disease and Joint Destruction

• The synovial membrane (normally 1-2 cell layers) transforms into a hypertrophic, invasive mass called pannus - composed of activated fibroblast-like synoviocytes (FLS), macrophages, T cells, B cells, and new blood vessels (angiogenesis)
• FLS are key effector cells: they acquire an aggressive, quasi-malignant phenotype, secreting matrix metalloproteinases (MMPs), RANKL, and proinflammatory cytokines, and directly invade cartilage

• Neutrophils are abundant in synovial fluid, especially early in disease
• NETs activate RA synovial FLS to release proinflammatory cytokines, chemokines, and adhesion molecules
• NET products are internalized by FLS, which upregulate MHC class II and present NET-derived citrullinated peptides to CD4+ T cells, creating an amplification loop
• NET-derived elastase directly degrades cartilage matrix; PAD-2 released from damaged FLS further citrullinates cartilage fragments, perpetuating ACPA responses

• MMPs (collagenase, stromelysin) secreted by activated FLS and macrophages degrade the extracellular matrix of articular cartilage
• Chondrocytes themselves contribute to their own destruction under cytokine stimulation
• Pannus tissue contains extensive microvasculature bringing nutrients to sustain the hyperplastic tissue

• RANKL (receptor activator of NF-kB ligand) expressed on activated FLS and Th17 cells drives differentiation and activation of osteoclasts
• TNF-alpha and IL-1 further promote osteoclastogenesis
• The result: juxta-articular bone erosion - the radiographic hallmark of RA

Summary Diagram: Phases of RA Pathogenesis

GENETIC RISK                    ENVIRONMENTAL TRIGGERS
(HLA-DRB1/SE, PTPN22, PADI4)  (Smoking, Periodontal disease, Dysbiosis)
         |                               |
         └──────────────┬────────────────┘
                        ▼
          MUCOSAL PHASE (Years before symptoms)
          - Citrullination of host proteins by PADs
          - ACPA and RF production (IgA → IgG)
          - T & B cell activation at mucosal sites
                        |
                        ▼
          CLINICALLY EVIDENT DISEASE (Joint involvement)
          - Immune complex deposition in synovium
          - Complement activation / FcR engagement
          - Innate immune activation (macrophages, NK cells)
          - Th1/Th17 T cell infiltration
          - B cell/plasma cell local autoantibody production
                        |
                        ▼
          ESTABLISHED RA (Pannus formation)
          - Synovial hyperplasia (FLS + macrophages + vessels)
          - TNF / IL-6 / IL-1 / IL-17 cytokine network
          - MMP-driven cartilage degradation
          - RANKL-driven osteoclast activation → bone erosion
          - NET formation → amplified ACPA loop

• Firestein & Kelley's Textbook of Rheumatology, 2-Volume Set - Pathophysiology of Autoimmune Rheumatic Diseases; Neutrophil biology; Genetics of RA
• Rheumatology, 2-Volume Set (2022, Elsevier) - RA etiology, microbiome, periodontal disease, genetics, metabolomics
• Roitt's Essential Immunology - Immune complex-mediated synovial inflammation and pannus
• Miller's Review of Orthopaedics - Cytokine-driven joint destruction and osteoclastogenesis

Note on recent evidence: Recent systematic reviews (2024-2025) have focused on IL-33 immunomodulation in RA (PMID 38825072) and fracture risk meta-analysis (PMID 39955689). These do not contradict the established pathophysiologic framework above but highlight ongoing research into additional cytokine axes.